Despite this variable, HER2 and HER3 were expressed in most prostate cancer metastases, which suggests that T-DXd and P-DXd have potential to benefit a substantial number of patients with metastatic prostate cancer. Here, ERBB2 is linked to metastatic prostate carcinoma.